Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma

BACKGROUND: The relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeliger, Hendrik, Pozios, Ioannis, Assmann, Gerald, Zhao, Yue, Müller, Mario H., Knösel, Thomas, Kreis, Martin E., Bruns, Christiane J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206939/
https://www.ncbi.nlm.nih.gov/pubmed/30373552
http://dx.doi.org/10.1186/s12885-018-4973-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206939/
https://www.ncbi.nlm.nih.gov/pubmed/30373552
http://dx.doi.org/10.1186/s12885-018-4973-6

Ejemplares similares